

PUBLISHED BY PORTLAND PRESS ON BEHALF OF
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

© The Medical Research Society and the Biochemical Society 1993
ISSN 0143-5221

Printed in Great Britain by Bell and Bain Limited, Glasgow

Volume 84

AUTHOR INDEX

- Aikawa, A. 243–246
Alberti, K.G.M.M. 461–467
Alessandri, M. 313–317
Allen, M. 319–324
Al-Mahdi, S. 401–405
Anderson, R. 663–669
Anderson, Y. 645–649
Ardaillou, R. 31–39
Arm, J.P. 501–510
Arnold, J. 655–661
Ashmead, G.G. 401–405
Auletta, F.J. 401–405
Aurell, M. 41–45
Azzini, M. 611–617
- Bakran, A. 243–246
Bárány, P. 441–447
Barnes, P.J. 391–399
Bassey, E.J. 331–337
Batt, R.M. 339–348
Benn, J. 87–93
Bergström, J. 441–447
Bernich, P. 611–617
Bijlsma, J.A. 627–632
Blas, S.D. 217–223
Bode-Böger, S.M. 517–524
Böger, R.H. 517–524
Bone, J.M. 231–235
Borg, M. 377–379
Boulet, L.P. 73–78
Boulton-Jones, J.M. 449–454
Braatvedt, G.D. 193–199,
201–207
Brown, D. 377–379
Brown, M.J. 55–60
Bruce, S.A. 95–98
Butcher, G.P. 339–348
- Cakaloglu, Y. 675–679
Calder, G. 99–104
Calmus, Y. 185–192
Campbell, I.T. 655–661
Cardoso, J.E. 185–192
Carney, S. 455–460
Casey, A. 565–571
Castillo, M.A. 281–286
Castrignano, R. 51–54
- Catalano, C. 461–467
Catell, W.R. 619–626
Chalon, S. 599–604
Chaudhuri, K.R. 419–425
Cherruau, B. 185–192
Chinkes, D.L. 177–183
Christian, R. 435–440
Chung, K.F. 391–399
Clamp, J.R. 573–579
Clarke, R. 543–548
Coates, J. 663–669
Coe, C.I. 325–329
Corfield, A.P. 573–579
Cormier, Y. 73–78
Cornall, R.J. 257–262
Corrall, R.J.M. 193–199, 201–207
Corrocher, R. 611–617
Cotes, P.M. 319–324
Cowley, A.J. 263–270
Cox, H. 225–230
Critchley, M. 231–235
Crougneau, S. 185–192
- D'Angelo, A. 51–54
Darling, P. 543–548
Davenport, A.P. 55–60
Davies, H.M. 243–246
Davies, J.E. 133–139, 633–643
Davies, M.J. 407–412
Davis, F.B. 217–223
Davis, P.J. 217–223
Davis, S.S. 605–609
Dawnay, A. 619–626
Daykin, K. 151–157
De Dios Luna, J. 281–286
Deighton, N. 339–348
Delday, M.I. 651–654
Demolis, P. 599–604
Devlin, J.C. 655–661
Dewar, A. 391–399
Deziel, M.R. 217–223
Dick, J. 145–150
Diemel, L.T. 305–311
Ding, B. 339–348
Doherty, J.F. 169–175
Dore, C.J. 319–324
Douglas, N.J. 319–324
- Dubrey, S.W. 537–542
Düsing, R. 435–440
Dussaule, J.C. 31–39
- Ebihara, I. 349–356
Eeftinck Schattenkerk,
J.K.M. 209–216
Elia, M. 99–104, 559–563
Ellis, F. 663–669
Endert, E. 209–216
Esler, M. 225–230
Evans, B. 663–669
- Fanciullacci, M. 313–317
Farang, M.M. 387–390
Feldt-Rasmussen, B. 237–242
Ferrier, C. 225–230
Fitzpatrick, M.F. 319–324
Flynn, M.D. 201–207
Fogh-Andersen, N. 237–242
Folio, C.J. 549–557
Forfar, J.C. 413–417
Fox, J.G. 449–454
Franklyn, J.A. 61–67
Freedman, S. 671–673
Freyschuss, U. 441–447
Frier, B.M. 79–86
Frölich, J.C. 517–524
Frye, R.F. 681–685
Fukamizu, A. 21–29
Fukui, M. 349–356
Fung, K. 69–72
- Gammage, M.D. 61–67
Gammaro, L. 611–617
García Del Río, C. 281–286
Giannini, S. 51–54
Gibb, I. 461–467
Gibson, P.H. 651–654
Gillespie, S. 461–467
Gillies, A. 455–460
Gin, T. 69–72
Girelli, D. 611–617
Giudicelli, J.-F. 599–604
Golden, M.H.N. 169–175
Goldstein, D.S. 549–557
Gopinathan, V. 407–412

- Gosling, R.G. 593–597
 Gray, T.A. 477–482
 Green, A. 113–117
 Green, C.J. 655–661
 Green, N.K. 61–67
 Greenhaff, P.L. 565–571
 Griffin, G.E. 169–175
 Grimble, R.F. 105–112
 Grime, J.S. 231–235
 Gros, C. 31–39
 Grossman, E. 549–557
 Gurden, M.F. 663–669
 Gutzki, F.M. 517–524
 Guz, A. 671–673
- Habib, N. 185–192
 Hall, I.P. 151–157
 Halliwell, M. 193–199, 201–207
 Hamazaki, T. 511–516
 Hannedouche, T. 11–19
 Haro, J.M. 281–286
 Harries, U.J. 331–337
 Harris, R. 565–571
 Hassib, A.T. 387–390
 Haynes, W.G. 427–433, 485–500
 Haywood, S. 339–348
 Heagerty, A.M. 61–67
 Hedeman, H. 605–609
 Helwig, J.-J. 11–19
 Henley, M. 319–324
 Herlitz, H. 41–45
 Heyligenberg, R. 209–216
 Heys, S.D. 651–654
 Hipkin, L.J. 655–661
 Hjemdahl, P. 41–45
 Hoffman, J. 339–348
 Hommes, M.J.T. 209–216
 Hopkins, K.D. 593–597
 Hosoi, M. 21–29
 Houssin, D. 185–192
 Hughes, A.D. 287–295
 Hultman, E. 565–571
- Ikenaga, H. 469–475
 Illum, L. 605–609
 Imai, Y. 47–50
 Ishii, N. 469–475
 Itoh, H. 469–475
 Iwasaki, T. 271–280
- Jackson, M.J. 113–117, 339–348
 Jagasia, D.H. 645–649
 Jalan, R. 113–117
 Jankowski, J. 483
 Jensen, B.L. 1–10
- Jensen, G. 41–45
 Jeyaraj, P.R. 185–192
 Johnson, P.M. 243–246
 Johnstone, J. 663–669
 Jones, P.W. 159–167
 Judes, C. 11–19
- Kamerling, J.P. 573–579
 Kamper, A. 237–242
 Kastrup, J. 297–304
 Katsuki, M. 21–29
 Kawamura, K. 531–535
 Kawashima, S. 271–280
 Keiser, H.R. 549–557
 Kennedy, I. 663–669
 Khan, K. 99–104
 Kim, S. 21–29
 Kisor, D.F. 681–685
 Ko, Y. 435–440
 Kobayashi, M. 511–516
 Koide, H. 349–356
 Koomans, H.A. 627–632
 Kopin, I.J. 549–557
 Kren, V. 129–132
 Kristensen, J.K. 297–304
 Kroegel, C. 391–399
 Kubota, J. 531–535
 Kudsk, K.A. 681–685
 Kunes, J. 129–132
 Kurpad, A. 99–104, 559–563
- Lamb, E. 691–626
 Lane, R. 671–673
 Lawrence, W.D. 217–223
 Lecomte, J.M. 31–39
 Lee, J.A. 141–144
 Lee, M.R. 357–375
 Lee, T.H. 501–510
 Lee, T.W. 69–72
 Leehey, D.J. 525–529
 Legendre, C. 185–192
 Lehmann, E.D. 593–597
 Leslie, D.G. 537–542
 Leyssac, P.P. 237–242
 Lombard, M. 113–117
 Low, J.M. 69–72
 Lowe, N.M. 113–117
 Ludlam, C.A. 79–86
 Lupo, A. 611–617
- Macdonald, I.A. 263–270, 655–661
 MacGregor, I.R. 79–86
 Mackay, T. 319–324
 MacNeil, S. 477–482
- Maltby, P. 231–235
 Maltin, C.A. 651–654
 Marinos, G. 675–679
 Marsden, J. 675–679
 Martin, D.P. 663–669
 Massfelder, T. 11–19
 Mathias, C.J. 419–425
 Maule, S. 419–425
 McAdam, K.P.W.J. 169–175
 McCance, A.J. 413–417
 McCleery, J. 419–425
 McIver, B. 79–86
 McLaughlin, M.K. 401–405
 McLaughlin, P.J. 243–246
 Menini, C. 611–617
 Michel, C. 31–39
 Michelacci, S. 313–317
 Mignon, F. 31–39
 Miller, N.J. 407–412
 Milner, A. 407–412
 Moghimi, S.M. 605–609
 Moots, R.J. 585–591
 Morgan, T. 455–460
 Morris, B.W. 477–482
 Mountford, R.A. 573–579
 Mouri, T. 47–50
 Mulrooney, H.M. 105–112
 Murakami, K. 21–29
 Murakami, O. 47–50
 Musso, M.-J. 11–19
- Nakamura, N. 511–516
 Nakamura, T. 349–356
 Nettekoven, W. 435–440
 Nevison, I.M. 651–654
 Newrick, P.G. 193–199
 Ng, L.L. 133–139, 633–643
 Nicolodi, M. 313–317
 Nishian, K. 271–280
 Nishimura, H. 531–535
 Nobile, M. 51–54
 Nozuki, M. 47–50
- O'Connor, B.M. 537–542
 O'Donnell, M. 537–542
 Oka, T. 531–535
 Oldfield, W.L.G. 159–167
 Olivieri, O. 611–617
 Olsen, M.H. 237–242
 Olsen, N.V. 237–242
 Orchard, C.H. 141–144
 O'Reilly, D.StJ. 449–454
- Papageorgiou, A. 543–548
 Parker, J.R. 593–597

- Pati, T. 51–54
 Pavitt, D. 419–425
 Pell, A.C.H. 79–86
 Pellegrini, F. 51–54
 Pencharz, P.B. 543–548
 Peraldi, M.N. 31–39
 Peters, T.J. 675–679
 Petersen, L.J. 297–304
 Pettersson, E. 441–447
 Phillips, A.D. 377–379
 Phillips, S.K. 95–98
 Plum, I. 237–242
 Pohlova, I. 129–132
 Pravenec, M. 129–132
 Pride, N.B. 325–329

 Quin, J.D. 449–454
 Quinn, P. 133–139

 Rabelink, T.J. 627–632
 Radda, G.K. 645–649
 Rajagopalan, B. 645–649
 Rampton, D.S. 381–386
 Ray, C. 455–460
 Raynes, J.G. 169–175
 Reaveley, D.A. 537–542
 Rennie, M.J. 655–661
 Rhodes, J.M. 113–117, 339–348,
 483
 Rice-Evans, C. 407–412
 Ritchie, I.K. 651–654
 Romijn, J.A. 209–216
 Rooke, K.M. 95–98
 Rosenblatt, J. 177–183
 Rustom, R. 231–235

 Sabio, J.M. 281–286
 Sachinidis, A. 435–440
 Safe, A. 573–579
 Sagara, M. 21–29
 Samuels, T.A. 655–661
 Saruta, T. 469–475
 Sauerwein, H.P. 209–216,
 247–256
 Saussine, C. 11–19
 Schauer, R. 573–579

 Schoenl, M. 217–223
 Schofield, J.P. 119–128
 Scrimgeour, C.M. 655–661
 Seed, M. 537–542
 Sekino, H. 47–50
 Sells, R.A. 243–246
 Sériès, F. 73–78
 Sever, P.S. 287–295
 Shah, N. 141–144
 Sheppard, M.C. 61–67
 Short, A.H. 565–571
 Sicuteri, F. 313–317
 Siddle, N.C. 95–98
 Sidery, M.B. 263–270
 Simeoni, U. 11–19
 Sindrup, J.H. 297–304
 Skøtt, O. 1–10
 Smith, K. 655–661
 Smith, M.W. 377–379
 Smith, P.R. 87–93
 Smith, S.F. 381–386
 Soderlund, K. 565–571
 Somani, H.H. 87–93
 Sone, M. 47–50
 Sonksen, P.H. 87–93, 593–597
 Stanners, A. 193–199, 201–207
 Stanzial, A.M. 611–617
 Stevens, T.R.J. 381–386
 Stockdale, H.R. 231–235
 Strand-Gaard, S. 237–242
 Strong, P. 663–669
 Sun, B. 55–60
 Sunman, W. 287–295
 Suzuki, H. 469–475
 Symons, M.C.R. 339–348

 Takahashi, K. 47–50
 Takahashi, T. 349–356
 Takaori, K. 21–29
 Taki, H. 511–516
 Tam, R.C. 319–324
 Tasca, A. 51–54
 Thomaidis, T. 419–425
 Thompson, C.H. 645–649
 Thornalley, P.J. 87–93
 Tomino, Y. 349–356

 Tomlinson, D.R. 305–311
 Totsune, K. 47–50
 Tredger, J.M. 675–679
 Tsigos, C. 305–311
 Tsikas, D. 517–524

 Ueyama, M. 531–535

 Van der Poll, T. 247–256
 Vargas, F. 281–286
 Venge, P. 391–399
 Vetter, H. 435–440
 Villi, G. 51–54
 Vliegthart, J.F.G. 573–579
 Volkmann, R. 41–45
 Vrbova, G. 145–150

 Wagner, S.A. 573–579
 Ward, R.G. 243–246
 Warren, J.B. 581–584
 Watson, J.S. 651–654
 Webb, D.J. 427–433, 485–500
 Webb, G.D. 401–405
 Weskott, H.-P. 517–524
 White, A. 305–311
 White, J. 141–144
 Whittom, R. 73–78
 Whyte, K.F. 319–324
 Widdop, S. 151–157
 Wieczorek, A.J. 435–440
 Wieczorek, I. 79–86
 Williams, R. 675–679
 Wilson, R.C. 159–167
 Winocour, P.H. 461–467
 Woledge, R.C. 95–98
 Wolfe, R.R. 177–183
 Wolfovitz, E. 549–557
 Wroblewski, H. 297–304
 Wykes, L.J. 543–548

 Yamamoto, K. 21–29
 Yamazaki, K. 511–516
 Young, R.J. 305–311
 Yukawa, T. 391–399

 Zicha, J. 129–132

Volume 84

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Editorial Reviews.

- O-Acetylation**
 - sialic acids, gastric aspirates 573–579
- N-Acetyl- β -D-glucosaminidase**
 - urine, diabetes 469–475
- Acidosis**
 - calcium sensitizers, myofilaments 141–144
- Acquired immunodeficiency syndrome**
 - glucose metabolism 209–216
- Active renin**
 - transgenic mouse, sodium depletion 21–29
- Acute glycaemic control**
 - retinol-binding protein, insulin-dependent diabetes 461–467
- Acute-phase response**
 - malnutrition 169–175
- Adenosine A₁-receptors**
 - non-esterified fatty acids 663–669
- Adenosine triphosphatase**
 - erythrocytes, menstrual cycle 401–405
- Adipose tissue blood flow**
 - nocturnal fluctuations, local nervous blockade 297–304
 - xenon 559–563
- Adrenaline**
 - splanchnic blood flow, hypoglycaemia 201–207
- β -Adrenoceptor blockade**
 - splanchnic blood flow, hypoglycaemia 201–207
- β -Adrenoceptor desensitization**
 - airway smooth muscle, cyclic AMP 151–157
- β -Adrenoceptors**
 - metoprolol, noradrenaline 413–417
- Advanced glycation end product**
 - pyrraline, diabetic complications 87–93
- Ageing**
 - muscle strength, disuse 331–337
 - muscle strength, hormone replacement therapy 95–98
 - sialic acids, gastric aspirates 573–579
- Airflow resistance**
 - hypoxaemia, chronic obstructive pulmonary disease 325–329
- Airway smooth muscle**
 - β -adrenoceptor desensitization, cyclic AMP 151–157
- Alanine aminopeptidase**
 - urine, diabetes 469–475
- Albumin**
 - nephrotic syndrome 627–632
- Alcohol**
 - blood flow, superior mesenteric artery 419–425
 - zinc kinetics, liver 113–117
- Alcoholic liver disease**
 - free radicals, electron paramagnetic resonance spectroscopy 339–348
- Alkaline phosphatase**
 - urine, diabetes 469–475
- Altitude**
 - breathlessness, exercise 159–167
- Amiloride**
 - pH regulation, bicarbonate 133–139
- Amino acids**
 - protein synthesis, flooding dose technique 177–183
- Amylase**
 - glomerular charge selectivity 449–454
- Anaemia**
 - erythropoietin, blood pressure 47–50
 - erythropoietin, exercise 441–447
 - microspheres, spleen 605–609
- Angiotensin**
 - pressor sensitivity, cirrhosis 525–529
 - renin secretion 1–10*
 - vascular smooth muscle cell, insulin 435–440
- Antidiuretic hormone**
 - distal nephron, somatostatin 455–460
 - insulin 281–286
- Antigens**
 - cytotoxic T lymphocytes, class I major histocompatibility complex 585–591
- Antioxidant**
 - 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid), premature neonates 407–412

- Anti-renin antibody
transgenic mouse 21–29
- Aortic compliance
biochemical correlates 593–597
- Aortic distensibility
biochemical correlates 593–597
- Aortic rings
angiotensin, cirrhosis 525–529
- Aortocaval fistula
haemodynamics, renal function 531–535
- Aprotinin
early and late renal catabolism 231–235
- Arteriovenous exchange
glycerol, muscle 99–104
- Aspirin
endothelium, veins 427–433
platelet aggregation 517–524
- Asthma
 β -adrenoceptor desensitization, cyclic
AMP 151–157
eosinophils, platelet-activating factor 391–399
histamine challenge, collateral ventilation 73–78
leukotrienes 501–510*
- Atherosclerosis
chronic renal failure, selenium 611–617
- Atrial natriuretic peptide
sodium excretion, chronic renal failure 31–39
- Atrophy
 β -adrenoceptor agonists 651–654
- Baroreceptor
renin secretion 1–10*
- Bicarbonate
pH regulation, cardiac myocytes 133–139
- Bile
intestinal absorption, cyclosporin A 675–679
- Blood flow
elderly, food ingestion 263–270
muscle, xenon 559–563
superior mesenteric artery, alcohol 419–425
- Blood flow velocity
transcranial Doppler technique,
repeatability 599–604
- Blood pressure
alcohol 419–425
elderly, food ingestion 263–270
endothelin 485–500*
endothelin, erythropoietin 47–50
insulin 281–286
renal renin activity, renin gene 129–132
- Breathlessness
exercise, altitude 159–167
- Ca^{2+} -adenosine triphosphatase
calmodulin, thyroxine 217–223
- Calcitonin-gene-related peptide
cerebrospinal fluid, diabetic
neuropathy 305–311
coronary artery, quantitative
autoradiography 55–60
- Calcium
acidosis, cardiotonics 141–144
parathyroid hormone, renin secretion 11–19
renin secretion 1–10*
- Calcium sensitizers
acidosis, myofilaments 141–144
- Calmodulin
erythrocyte membranes, thyroxine 217–223
- Carbamoyl-phosphate synthetase gene
DNA sequencing, molecular
evolution 119–128
- Cardiac hypertrophy
aortocaval fistula 531–535
- Cardiac myocytes
pH regulation, bicarbonate 133–139
- Cardiac output
elderly, food ingestion 263–270
thermodilution, aortocaval fistula 531–535
- Cardiopulmonary baroreceptors
forearm vasodilatation, congestive heart
failure 271–280
- Cardiotonics
acidosis, myofilaments 141–144
- Cardiovascular disease
endothelin 485–500*
- Catecholamines
hypercapnia 69–72
natriuresis 549–557
renovascular hypertension, renin–angiotensin
system 41–45
- CD8
peptides, cytotoxic T lymphocytes 585–591
- Cell activation
platelet-activating factor, asthma 391–399
- Central nervous factors
adipose tissue blood flow, nocturnal
fluctuations 297–304
- Cerebral artery
blood flow velocity, transcranial Doppler
technique 599–604
- Cerebrospinal fluid
converting enzyme, enalapril 313–317
neuropeptides, diabetes neuropathy 305–311
- Charge selectivity
glomerulus, amylase 449–454
- Cholesterol
fibroblasts, intracellular pH 633–643
- Chromium
diabetes 477–482
- Chronic bronchitis

- nocturnal hypoxaemia, erythropoietin 319–324
- Chronic obstructive pulmonary disease
hypoxaemia, airflow resistance 325–329
nocturnal hypoxaemia, erythropoietin 319–324
- Chronic renal failure
selenium, glutathione peroxidase 611–617
sodium excretion, neutral endopeptidase inhibitor 31–39
- Circadian rhythm
erythropoietin, chronic obstructive pulmonary disease 319–324
- Cirrhosis
portal pressure, isolated perfused rat liver 185–192
pressor sensitivity, angiotensin 525–529
- Class I major histocompatibility complex
peptides, cytotoxic T lymphocytes 585–591
- Clenbuterol
muscle strength 651–654
- Coagulation
diabetes, venous occlusion 79–86
- Collateral ventilation
histamine challenge, asthma 73–78
- Colon
mucin, sulphation 483
- Congestive heart failure
forearm vasodilatation, cardiopulmonary baroreceptors 271–280
- Constant infusion technique
protein synthesis, mathematical modelling 177–183
- Continuous ambulatory peritoneal dialysis
ultrafiltration failure, glycated albumin 619–626
- Contractile properties
overloaded muscle, *mdx* mice 145–150
- Converting enzyme
cerebrospinal fluid, enalapril 313–317
- Coronary artery
calcitonin-gene-related peptide, quantitative autoradiography 55–60
- Corticosteroid therapy
inflammatory bowel disease, lipocortin-I antibodies 381–386
- C-reactive protein
malnutrition 169–175
- Creatine supplementation
muscle fatigue 565–571
- Critical illness
protein kinetics 655–661
- Crohn's disease
lipocortin-I antibodies, corticosteroid therapy 381–386
- Cyclic AMP
 β -adrenoceptor desensitization, asthma 151–157
endothelium, oedema 581–584*
- Cyclic GMP
sodium excretion, chronic renal failure 31–39
- 3':5'-Cyclic nucleotide phosphodiesterase
calmodulin, thyroxine 217–223
- Cyclic nucleotides
renin secretion 1–10*
- Cyclosporin A
intestinal absorption, pharmacokinetics 675–679
- Cytokines
sepsis, metabolism 247–256*
- Cytotoxic T lymphocytes
peptides, class I major histocompatibility complex 585–591
- Degranulation
platelet-activating factor, asthma 391–399
- Desensitization
 β -adrenoceptors, cyclic AMP 151–157
- Diabetes
chromium 477–482
enzymuria 469–475
haemostasis, venous occlusion 79–86
lipoproteins, twins 537–542
microsatellites, non-obese diabetic mouse 257–262
neuropeptides, cerebrospinal fluid 305–311
retinol-binding protein, acute glycaemic control 461–467
- Diabetic complications
Maillard reaction, pyrrolidine 87–93
- Diabetic neuropathy
neuropeptides, cerebrospinal fluid 305–311
- Dialysis
glutathione peroxidase, selenium 611–617
- Diclofenac sodium
microsomal enzymes, triacylglycerol 387–390
- Dietary fat
tumour necrosis factor, metabolic responses 105–112
- Dihomo- γ -linolenic acid
intravenous infusion, leukotriene B₄ 511–516
- Dihydroxyphenylalanine
dopamine, natriuresis 549–557
- Dipeptidyl aminopeptidase IV
urine, diabetes 469–475
- Distal nephron
water permeability, somatostatin 455–460
- Disuse
muscle strength, ageing 331–337
- DNA sequencing
carbamoyl-phosphate synthetase gene, molecular evolution 119–128
- DNA synthesis
vascular smooth muscle cell, insulin 435–440

- Dopamine
 dihydroxyphenylalanine, natriuresis 549–557
 kidney, hypertension 357–375*
 renal function, lithium 237–242
- Doppler ultrasound
 splanchnic blood flow, adrenaline 201–207
 splanchnic blood flow, glucagon 193–199
- Drug carriers
 spleen, anaemia 605–609
- Effective renal plasma flow
 dopamine, lithium 237–242
- Elderly
 haemodynamics, food ingestion 263–270
- Electrolyte transport
 distal nephron, somatostatin 455–460
- Electron paramagnetic resonance spectroscopy
 free radicals, alcoholic liver disease 339–348
- EMD 57033
 acidosis, myofilaments 141–144
- Emphysema
 nocturnal hypoxaemia, erythropoietin 319–324
- Enalapril
 converting enzyme, cerebrospinal fluid 313–317
- Endothelial factors
 renin secretion 1–10*
- Endothelin
 blood pressure, erythropoietin 47–50
 nitric oxide, veins 427–433
 physiology and role in disease 485–500*
- Endothelium
 free radicals, superoxide dismutase 287–295
 oedema, cyclic AMP 581–584*
- Endotoxin
 tumour necrosis factor- α , metabolism 247–256*
- Energy expenditure
 critical illness 655–661
- Energy metabolism
 creatine supplementation 565–571
- Enteric disease
 intestinal stem cells, microvillus 377–379
- Enterocyte differentiation
 microvillus, enteric disease 377–379
- Eosinophils
 morphological changes, platelet-activating factor 391–399
- Epidermal growth factor
 vascular smooth muscle cell, insulin 435–440
- Erythrocytes
 sodium–potassium pump, menstrual cycle 401–405
- Erythropoietin
 blood pressure, endothelin 47–50
 haemodialysis, exercise 441–447
 nocturnal hypoxaemia, chronic obstructive pulmonary disease 319–324
- Exercise
 breathlessness, altitude 159–167
 haemodialysis, erythropoietin 441–447
- Extraction ratio
 Indocyanine Green, model 681–685
- Fat
 sepsis, tumour necrosis factor- α 247–256*
- Fatigue
 creatine supplementation 565–571
- Ferryl myoglobin
 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid), antioxidant 407–412
- Fibrinolysis
 diabetes, venous occlusion 79–86
- Fibroblasts
 intracellular pH, 3-hydroxy-3-methylglutaryl-CoA reductase 633–643
- Flooding dose technique
 protein synthesis, mathematical modelling 177–183
- Focal glomerular sclerosis
 tumour necrosis factor 349–356
- Food ingestion
 haemodynamics, elderly 263–270
- Forearm vasodilatation
 cardiopulmonary baroreceptors, congestive heart failure 271–280
- Fractional synthesis rate of protein
 flooding dose technique, mathematical modelling 177–183
- Free radicals
 alcohol, liver 339–348
 premature neonates 407–412
 vascular smooth muscle, superoxide dismutase 287–295
- Gastric aspirates
 sialic acids, ageing 573–579
- Gene mapping
 non-obese diabetic mouse 257–262
- Gene structure
 polymerase chain reaction, molecular evolution 119–128
- Glomerulus
 charge selectivity, amylase 449–454
- Glucagon
 splanchnic blood flow, hypoglycaemia 193–199
- Glucose metabolism
 acquired immunodeficiency syndrome 209–216
 sepsis, tumour necrosis factor- α 247–256*
- γ -Glutamyl transpeptidase
 urine, diabetes 469–475
- Glutathione peroxidase

- selenium, chronic renal failure 611–617
- Glycated albumin
 - continuous ambulatory peritoneal dialysis, ultrafiltration failure 619–626
- Glycation
 - ultrafiltration failure, continuous ambulatory peritoneal dialysis 619–626
- Glycerol
 - arteriovenous exchange, muscle 99–104
- GR79236
 - non-esterified fatty acids 663–669
- Haemodialysis
 - endothelin, blood pressure 47–50
 - exercise, erythropoietin 441–447
- Haemostasis
 - diabetes, venous occlusion 79–86
- Handgrip
 - ageing, disuse 331–337
- Health
 - muscle strength, ageing 331–337
- Histamine challenge
 - collateral ventilation, asthma 73–78
- Hormone replacement therapy
 - muscle strength, ageing 95–98
- 3-Hydroxy-3-methylglutaryl-CoA reductase
 - intracellular pH, fibroblasts 633–643
- Hypercalciuria
 - renal stone disease, vitamin D 51–54
- Hypercapnia
 - catecholamines 69–72
- Hyperoxaluria
 - renal stone disease, vitamin D 51–54
- Hypertension
 - kidney, dopamine 357–375*
- Hypocapnia
 - catecholamines 69–72
- Hypoglycaemia
 - haemostasis 79–86
 - splanchnic blood flow, adrenaline 201–207
 - splanchnic blood flow, glucagon 193–199
- Hypoxaemia
 - airflow resistance, chronic obstructive pulmonary disease 325–329
 - erythropoietin, chronic obstructive pulmonary disease 319–324
- Inactive renin
 - transgenic mouse 21–29
- Indocyanine Green
 - hepatic extraction ratio, model 681–685
- Indomethacin
 - pressor sensitivity, cirrhosis 525–529
- Infant formulae
 - whey protein, non-protein nitrogen 543–548
- Inflammation
 - dihomo- γ -linolenic acid, leukotriene B₄ 511–516
 - endothelium, oedema 581–584*
- Inflammatory bowel disease
 - lipocortin-I antibodies, corticosteroid therapy 381–386
- Insulin
 - blood pressure, antidiuretic hormone 281–286
 - DNA synthesis, vascular smooth muscle cell 435–440
 - haemostasis 79–86
 - lipoproteins, twins 537–542
- Insulin sensitivity
 - acquired immunodeficiency syndrome 209–216
- Insulin-dependent diabetes
 - retinol-binding protein, acute glycaemic control 461–467
- Insulin-like growth factor-I
 - aortic distensibility 593–597
- Intestinal absorption
 - cyclosporin A, pharmacokinetics 675–679
- Intestinal stem cells
 - microvillus, enteric disease 377–379
- Intracellular pH
 - fibroblasts, 3-hydroxy-3-methylglutaryl-CoA reductase 633–643
 - skeletal muscle, tri-iodothyronine 645–649
- Introns
 - carbamoyl-phosphate synthetase gene, molecular evolution 119–128
- Iron
 - alcoholic liver disease, free radicals 339–348
- Isoprenaline
 - renin secretion 11–19
- Isotope-wash-out technique
 - adipose tissue blood flow, nocturnal fluctuations 297–304
- Juxtaglomerular cells
 - control of renin secretion 1–10*
 - renin secretion, parathyroid hormone 11–19
- Kidney
 - hypertension, dopamine 357–375*
- Laser Doppler flowmetry
 - renal blood flow, aortocaval fistula 531–535
- Leucine
 - protein kinetics, critical illness 655–661
 - protein synthesis, flooding dose technique 177–183
- Leukotriene B₄
 - dihomo- γ -linolenic acid, intravenous infusion 511–516
- Leukotrienes

- asthma 501–510*
- Lipids
 - aortic distensibility 593–597
 - twins, diabetes 537–542
- Lipocortin-I antibodies
 - inflammatory bowel disease, corticosteroid therapy 381–386
- Lipoproteins
 - twins, diabetes 537–542
- Lithium
 - renal function, dopamine 237–242
- Liver
 - alcohol, free radicals 339–348
 - zinc kinetics, alcohol 113–117
- Local nervous blockade
 - adipose tissue blood flow, nocturnal fluctuations 297–304
- Low-birthweight infants
 - non-protein nitrogen, whey protein 543–548
- Low-density lipoprotein-cholesterol
 - aortic distensibility 593–597
- Low-molecular-mass proteins
 - early and late renal catabolism 231–235
- Low-molecular-mass proteinuria
 - insulin-dependent diabetes, acute glycaemic control 461–467
- Lower leg
 - adipose tissue blood flow, nocturnal fluctuations 297–304
- Lower-body negative pressure
 - forearm vasodilatation, congestive heart failure 271–280
- Macula densa
 - renin secretion 1–10*
- Maillard reaction
 - pyrraline, diabetic complications 87–93
- Malnutrition
 - acute-phase response 169–175
- mdx* mice
 - overloaded muscle, contractile properties 145–150
- Menisectomy
 - β -adrenoceptor agonists 651–654
- Menopause
 - muscle strength, hormone replacement therapy 95–98
- Menstrual cycle
 - erythrocytes, sodium–potassium pump 401–405
- Metabolic responses
 - sepsis, tumour necrosis factor- α 247–256*
 - tumour necrosis factor, dietary fat 105–112
- Metoprolol
 - β -adrenoceptors, noradrenaline 413–417
- Microcirculation
 - nocturnal fluctuations, local nervous blockade 297–304
 - permeability, oedema 581–584*
- Microsatellites
 - non-obese diabetic mouse 257–262
- Microsomal enzymes,
 - phenylbutazone, triacylglycerol 387–390
- Microspheres
 - spleen, anaemia 605–609
- Microvillus
 - intestinal stem cells, enteric disease 377–379
- Mitochondria
 - liver, alcohol 339–348
- Molecular evolution
 - introns, carbamoyl-phosphate synthetase gene 119–128
- N^G -Monomethyl-L-arginine
 - endothelium, veins 427–433
- Mucin
 - sulphation, colon 483
- Multiple organ failure
 - protein kinetics 655–661
- Muscle
 - blood flow, xenon 559–563
 - fatigue, creatine supplementation 565–571
 - glycerol, arteriovenous exchange 99–104
- Muscle strength
 - β -adrenoceptor agonists 651–654
 - ageing, disuse 331–337
 - ageing, hormone replacement therapy 95–98
- Myofilaments
 - acidosis, calcium sensitizers 141–144
- Natriuresis
 - dihydroxyphenylalanine, dopamine 549–557
 - dopamine, lithium 237–242
- Nephrotic syndrome
 - volume expansion 627–632
- Nerve biopsy
 - neuropeptides, diabetic neuropathy 305–311
- Neutral endopeptidase
 - cerebrospinal fluid, enalapril 313–317
- Neutral endopeptidase inhibitor
 - sodium excretion, chronic renal failure 31–39
- Nitric oxide
 - endothelium, veins 427–433
 - superoxide dismutase, vascular smooth muscle 287–295
 - vasodilatation, oedema 581–584*
- Nitrogen
 - whey protein, infant formulae 543–548
- Non-esterified fatty acids
 - adenosine A_1 -receptors 663–669
- Non-insulin-dependent diabetes
 - enzymuria 469–475

- Non-insulin-mediated glucose uptake
acquired immunodeficiency syndrome 209–216
- Non-obese diabetic mouse
microsatellites 257–262
- Non-protein nitrogen
whey protein, infant formulae 543–548
- Noradrenaline
 β -adrenoceptors, metoprolol 413–417
cardiopulmonary baroreceptors, congestive heart failure 271–280
- Noradrenaline kinetics
prehypertension 225–230
- Octreotide
splanchnic blood flow, hypoglycaemia 193–199
- Oedema
endothelium, cyclic AMP 581–584*
- Osmotic forces
renin secretion 1–10*
- Overloaded muscle
progressive deterioration, *mdx* mice 145–150
- ³¹P nuclear magnetic resonance spectroscopy
intracellular pH, tri-iodothyronine 645–649
- Pain
neuropeptides, cerebrospinal fluid 305–311
- Painful neuropathy
neuropeptides, cerebrospinal fluid 305–311
- Parathyroid hormone
calcium, renin secretion 11–19
- Peptides
cytotoxic T lymphocytes, class I major histocompatibility complex 585–591
- Permeability
endothelium, oedema 581–584*
- Peroxisome
liver, alcohol 339–348
- pH regulation
bicarbonate, cardiac myocytes 133–139
- Phenylbutazone
microsomal enzymes, triacylglycerol 387–390
- Phosphocreatine
muscle fatigue, creatine supplementation 565–571
- Platelet aggregation
aspirin infusion 517–524
- Platelet-activating factor
eosinophils, asthma 391–399
- Platelets
glutathione peroxidase, selenium 611–617
- Plethysmography
blood flow, limb 559–563
- Polycythaemia
erythropoietin, chronic obstructive pulmonary disease 319–324
- Polymerase chain reaction
gene structure, molecular evolution 119–128
- Portal hypertension
isolated perfused rat liver, cirrhosis 185–192
- Portal pressure
isolated perfused rat liver, cirrhosis 185–192
- Posture
retinol-binding protein, insulin-dependent diabetes 461–467
- Potassium
erythrocytes, menstrual cycle 401–405
- Pregnancy
erythrocytes, sodium–potassium pump 401–405
- Prehypertension
noradrenaline kinetics 225–230
- Premature neonates
antioxidant, 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) 407–412
- Pressor sensitivity
angiotensin, cirrhosis 525–529
- Progressive deterioration
overloaded muscle, *mdx* mice 145–150
- Prostacyclin
endothelium, veins 427–433
- Prostaglandins
pressor sensitivity, cirrhosis 525–529
renin secretion 1–10*
- Protein kinetics
critical illness 655–661
- Protein synthesis
flooding dose technique, mathematical modelling 177–183
- Proteinuria
glomerular charge selectivity, amylase 449–454
- Proto-oncogenes
thyroid hormones, ventricular hypertrophy 61–67
- Proton efflux
skeletal muscle, tri-iodothyronine 645–649
- Pulmonary resistance
continuous measurement and display 671–673
- Puromycin aminonucleoside nephrosis
tumour necrosis factor 349–356
- Pyrraline
Maillard reaction, diabetic complications 87–93
- Quantitative autoradiography
calcitonin-gene-related peptide, coronary artery 55–60
- Recombinant inbred strains
renin gene, renal renin activity 129–132
- Rehabilitation
 β -adrenoceptor agonists 651–654

- Renal catabolism
 low-molecular-mass proteins 231–235
- Renal disease
 endothelin 485–500*
- Renal function
 dopamine, lithium 237–242
 laser Doppler flowmetry, aortocaval fistula 531–535
- Renal nerves
 renin secretion 1–10*
- Renal renin activity
 renin gene, blood pressure 129–132
- Renal stone disease
 hyperoxaluria, vitamin D 51–54
- Renal transplantation
 uromodulin, tumour necrosis factor 243–246
- Renin
 transgenic mouse, sodium depletion 21–29
- Renin gene
 renal renin activity, blood pressure 129–132
- Renin secretion
 control mechanisms 1–10*
 parathyroid hormone, calcium 11–19
- Renin–angiotensin system
 catecholamines, renovascular hypertension 41–45
- Renovascular hypertension
 catecholamines, renin–angiotensin system 41–45
- Repeatability
 transcranial Doppler technique, blood flow velocity 599–604
- Respiratory disease
 endothelin 485–500*
- Retinol-binding protein
 insulin-dependent diabetes, acute glycaemic control 461–467
- Selenium
 glutathione peroxidase, chronic renal failure 611–617
- Sepsis
 stress hormones, tumour necrosis factor- α 247–256*
- Serum amyloid A
 malnutrition 169–175
- Sialic acids
 gastric aspirates, ageing 573–579
- Simvastatin
 intracellular pH, fibroblasts 633–643
- Skeletal muscle
 proton efflux, tri-iodothyronine 645–649
- Skin
 blood flow, xenon 559–563
- Sodium
 erythrocytes, menstrual cycle 401–405
 kidney, dopamine 357–375*
- Sodium depletion
 renin, transgenic mouse 21–29
- Sodium excretion
 chronic renal failure, neutral endopeptidase inhibitor 31–39
- Sodium–proton antiport
 fibroblasts, 3-hydroxy-3-methylglutaryl-CoA reductase 633–643
 pH regulation, bicarbonate 133–139
 skeletal muscle, tri-iodothyronine 645–649
- Somatostatin
 water permeability, distal nephron 455–460
- Specific binding
 calcitonin-gene-related peptide, coronary artery 55–60
- Splanchnic blood flow
 adrenaline, hypoglycaemia 201–207
 hypoglycaemia, glucagon 193–199
- Spleen
 microspheres, anaemia 605–609
- Spontaneously hypertensive rats
 renin gene, renal renin activity 129–132
- Stable isotopes
 non-protein nitrogen, infant formulae 543–548
 zinc kinetics, alcohol 113–117
- Stress hormones
 sepsis, tumour necrosis factor- α 247–256*
- Subcellular fractionation
 liver, alcohol 339–348
- Subcutaneous blood flow
 nocturnal fluctuations, local nervous blockade 297–304
- Substance P
 cerebrospinal fluid, diabetic neuropathy 305–311
- Sulphation
 mucin, colon 483
- Superior mesenteric artery
 blood flow, alcohol 419–425
- Superoxide dismutase
 free radicals, vascular smooth muscle 287–295
- Sympathetic nervous system
 natriuresis 549–557
 prehypertension 225–230
- Tamm–Horsfall glycoprotein
 tumour necrosis factor, renal transplantation 243–246
- Thermodilution
 cardiac output, aortocaval fistula 531–535
- Thermoregulation
 adipose tissue blood flow, nocturnal fluctuations 297–304
- Thromboxane B₂ synthesis

- aspirin infusion 517–524
- Thyroid hormones
 - proto-oncogenes, ventricular hypertrophy 61–67
- Thyroxine
 - calmodulin, erythrocyte membranes 217–223
- Trace metals
 - diabetes 477–482
- Transcranial Doppler technique
 - blood flow velocity, repeatability 599–604
- Transgenic mouse
 - renin, sodium depletion 21–29
- Tri-iodothyronine
 - intracellular pH, ^{31}P nuclear magnetic resonance spectroscopy 645–649
- Triacylglycerol
 - adenosine A_1 -receptors 663–669
 - microsomal enzymes, phenylbutazone 387–390
- Trolox
 - antioxidant, premature neonates 407–412
- Tumour necrosis factor
 - focal glomerular sclerosis 349–356
 - metabolic responses, dietary fat 105–112
 - stress hormones, sepsis 247–256*
 - uromodulin, renal transplantation 243–246
- Twins
 - lipoproteins, diabetes 537–542
- Ulcerative colitis
 - lipocortin-I antibodies, corticosteroid therapy 381–386
 - mucin, sulphation 483
- Ultrafiltration failure
 - continuous ambulatory peritoneal dialysis, glycated albumin 619–626
- Uraemia
 - haemodialysis, erythropoietin 441–447
- Urea
 - non-protein nitrogen, infant formulae 543–548
- Urinary 2,3-dinor-6-keto-prostaglandin $\text{F}_{1\alpha}$
 - aspirin infusion 517–524
- Urinary 2,3-dinor-thromboxane B_2
 - aspirin infusion 517–524
- Urinary prostaglandin E_2
 - aspirin infusion 517–524
- Urine
 - enzymes, diabetes 469–475
- Urine concentration
 - distal nephron, somatostatin 455–460
- Uromodulin
 - tumour necrosis factor, renal transplantation 243–246
- Vascular smooth muscle
 - DNA synthesis, insulin 435–440
 - free radicals, superoxide dismutase 287–295
- Vasodilatation
 - oedema, nitric oxide 581–584*
- Veins
 - endothelium, nitric oxide 427–433
- Venous occlusion
 - haemostasis, diabetes 79–86
- Ventricular hypertrophy
 - proto-oncogenes, thyroid hormones 61–67
- Verapamil
 - renin secretion 11–19
- Vitamin D
 - hyperoxaluria, renal stone disease 51–54
- Volume expansion
 - nephrotic syndrome 627–632
- Water permeability
 - distal nephron, somatostatin 455–460
- Whey protein
 - non-protein nitrogen, infant formulae 543–548
- Xenon
 - blood flow, muscle 559–563
- ^{133}Xe -wash-out technique
 - adipose tissue blood flow, nocturnal fluctuations 297–304
- Zinc kinetics
 - stable isotope, alcohol 113–117